Alexion Pharmaceuticals (ALXN) Revenue and Net Income History
Historical revenue, operating income and net income for Alexion Pharmaceuticals (ALXN) over the last 10 years. The current TTM revenue for Alexion Pharmaceuticals as of January 19, 2018 is $3.08B.
|Medical||Medical - Biomedical and Genetics||$27.044B||$3.084B|
|Alexion Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.|